Debra Patt, MD, PhD, MBA, executive vice president at Texas Oncology, discusses her recent testimony to the US Senate on a case in which prior authorization caused a 6-week wait for a consult.
It is becoming harder for patients with cancer to receive the care they need within an appropriate time frame, said Debra Patt, MD, PhD, MBA, executive vice president at Texas Oncology, whose own experience has been bolstered by stories from other clinicians and the American Medical Association (AMA).
Transcript
You recently testified in the Senate about a prior authorization case in which you were told you would have to wait up to 6 weeks for a consult to treat your breast cancer patient with an innovative therapy. What have you heard from other oncologists since the AMA reported on this case?
Unfortunately, the burden of prior authorization is tremendous and growing. It substantially impacts patient care, frequently delaying and deterring appropriate patient care. What I testified about—which is a common practice—is that if you initially have denial from an insurance company in their PBM [pharmacy benefit manager] relationship, that they can go through a prior authorization process that should be rapid.
But the peer-to-peer review, what they told me was, “Dr Patt, we can't tell you when we're going to have someone call you for peer-to-peer review. But it will be sometime in the next 6 weeks, at 8 AM in the morning.” And so, I gave them my cell phone number. And I'm sort of at the mercy of when someone is going to call, not being able to schedule it. And that practice has become more and more prevalent.
I think it's a reflection of the vertical integration that we see in the payer markets between payers, [PBMs], and specialty pharmacy, and to some degree providers. What we've seen with this integration, the 6 top PBMs have about 80% of the market. And when that happens, there's an increase in formulary restrictions. You're going to get denials on things when they're not the preferred drug because there's formulary restrictions. And that's really related to preferential rebates in the insurance markets.
We're seeing in cancer care, where we have these new and novel innovative therapies, tremendous growth of this practice, and it makes it harder and harder for cancer patients to get the care that they need.
I have gotten a lot of feedback since my testimony, and that feedback from other doctors has been that they see the same thing, that they too have had patients for whom treatments weren't an option, because they had to wait an inappropriate amount of time for peer-to-peer review. The prior auth process delayed and deterred appropriate care, and that the natural consequence was that patients had worse cancer morbidity and mortality.
Dato-Dxd Shows Survival Improvements in HR+/HER2– Breast Cancer
September 29th 2023The dual primary end points of overall survival and progression-free survival were encouraging when patients with hormone receptor–positive (HR+), HER2-negative (HER2–) breast cancer were treated with datopotamab deruxtecan.
Read More
Nathan Walcker Discusses Value-Based Oncology Care Initiatives at FCS
September 8th 2023Nathan Walcker, CEO at Florida Cancer Specialists & Research Institute (FCS), highlights some of the recent partnerships and initiatives at FCS to improve community-based oncology care from a value-based perspective.
Listen
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Breast Cancer Risk Linked to Air Pollution Exposure
September 22nd 2023Data from 6 states—California, Florida, Louisiana, New Jersey, North Carolina, and Pennsylvania—and 2 metropolitan areas—Atlanta, Georgia, and Detroit, Michigan—collected through the National Institutes of Health–AARP Diet and Health Study were used for the investigation.
Read More
New CMS Models Target Transformation to Address Need for Health Equity
September 21st 2023"CMS cannot do this alone. We have to do this in partnership. So really thinking about providers and beneficiaries and how we do this together," Ellen Lukens, MPH, Center for Medicare and Medicaid Innovation, explained.
Read More
2 Clarke Drive
Cranbury, NJ 08512